NewsRx

Search our medical news database

Blood Safety

First platelet pathogen inactivation system receives CE clearance

Published in Hepatitis Weekly, November 25th, 2002

Subsidiaries of Baxter International Inc. (BAX), and Cerus Corporation (CERS) announced CE Mark declaration for the illuminator device for the Intercept Blood System.

This represents the final regulatory step before this first pathogen inactivation technology for platelets is available in Europe.

The Intercept Blood System is designed to protect patients by reducing the risk of transfusion-transmitted diseases through blood transfusions by inactivating certain known and potential emerging pathogens in blood components.

Application of this technology to platelets is the first to be approved and clinical trials are underway for use...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook